SecBot SecBot
8-K ·Filed Nov 10, 2026

ABUS

Arbutus Biopharma Corp
NEUTRAL
Impact 5/10
Horizonweeks Processed6d 19h ago SEC0001171843-26-007311
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor the Federal Circuit's Moderna 1498 appeal decision, which could unlock a $1.3B contingent payment. Watch for next steps on AB-101 clinical development after FDA lift. Track progress of international LNP lawsuits against Pfizer/BioNTech for potential future damages or settlements.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

ABUS drug pipeline →

AB-101

● Neutral Named in this 8-K
Impact
Phase
Phase 1a/1b
Time to market
AB-101 is in Phase 1a/1b trials; even if development proceeds smoothly, a potential approval is likely several years away given the early stage and the need for larger Phase 2 and Phase 3 trials.
Next catalyst
None dated

What to watchThe next catalyst for ABUS is Q3 2026 earnings on November 11, 2026 (tomorrow), which may include updates on AB-101's clinical development plans now that the FDA hold is lifted. For AB-101 specifically, watch for the company to announce the next phase of clinical trials in chronic hepatitis B patients. The clinical hold lift removes a key overhang, but the drug remains early-stage with no pivotal readout or PDUFA date on the horizon.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$3.82
T+0 close · Nov 10, 2026 · via day close
Latest settled
+1.57%
T+1 · $3.88
Vs SPY
+0.25%
α at T+1
Next horizon
T+5
in 4h
  1. T+0 · Nov 10 $3.82entry
  2. T+1 · 6d ago +1.57%α +0.25% · $3.88
  3. T+4 · todayOpen
  4. T+5 · in 4h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Arbutus reported Q3 2026 net income of $59.1M ($0.30/share), driven by a $67.3M dividend from Genevant, versus a $7.7M net loss in Q3 2025. Operating revenue was $0.3M, down from $0.5M a year ago. The company completed a $230M tender offer in October, repurchasing 23% of shares. The FDA lifted the clinical hold on AB-101, and new LNP patent lawsuits were filed in Japan and Canada against Pfizer/BioNTech. The Moderna 1498 appeal oral argument was held on Nov 5, with a decision pending.

Key Financial Metrics

EPS
$0.30
Revenue
$299.0K
est $1.4M · -78.6% · -43.5% YoY

Key Facts

  • Q3 2026 net income of $59.1M vs net loss of $7.7M in Q3 2025
  • Total revenue of $0.3M, down from $0.5M in Q3 2025
  • Cash and marketable securities of $337.5M as of Sept 30, 2026
  • Completed $230M modified Dutch auction tender offer in Oct 2026, repurchasing 46M shares (23% of outstanding)
  • Received $67.3M cash dividend from Genevant in Sept 2026
  • FDA lifted clinical hold on AB-101 (oral PD-L1 inhibitor) IND
  • Filed new LNP patent lawsuits in Japan and amended Canadian lawsuit against Pfizer/BioNTech
  • Moderna 1498 appeal oral argument held Nov 5, 2026, decision pending
  • Operating loss of $10.5M in Q3 2026 vs $8.7M in Q3 2025
  • R&D expenses decreased to $2.6M from $5.8M; G&A increased to $8.0M from $3.0M due to one-time executive bonuses

Financial Impact

Net income of $59.1M primarily from $67.3M Genevant dividend; operating loss of $10.5M; $230M returned to shareholders via tender offer

net incomecash positionshare countoperating expenses

Risk Factors

  • Operating revenue remains minimal ($0.3M) with no near-term product sales
  • Operating loss widened to $10.5M from $8.7M due to higher G&A expenses
  • Moderna 1498 appeal outcome is uncertain; contingent $1.3B payment may not materialize
  • LNP litigation against Pfizer/BioNTech is ongoing with no guaranteed outcome
  • Clinical-stage pipeline with no approved products; AB-101 development plans not yet defined

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-007311
Document: f8k_111026.htm0001171843-26-007311
Document: 0001171843-26-007311-index-headers.html0001171843-26-007311
Document: 0001171843-26-007311-index.html0001171843-26-007311
Document: 0001171843-26-007311.txt0001171843-26-007311
8-K Data (Synthetic)0001171843-26-007311

Track record

25 reports on ABUS

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +11.55% at T+20 after the Aug 12, 2026 report. 6 of 12 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
  3. Nov 16, 2026today SC 13G Neutral 3/10 Entry $4.07 Now $4.04 −0.74% settles Feb 12
  4. Nov 12, 20264d ago 8-K Neutral 2/10 Entry $4.03 Now $4.04 +0.25% settles Feb 10
  5. Nov 10, 20266d ago 8-K Neutral 5/10 Viewing Entry $3.82 Now $4.04 +5.76% settles Feb 8
  6. Nov 10, 20266d ago Press Release Neutral 4/10 No price data
  7. Nov 6, 202610d ago Institutional Cluster Bearish 4/10 Entry $3.66 Now $4.04 −10.53% settles Feb 4
  8. Oct 22, 202625d ago 8-K Bullish 6/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
  9. Oct 22, 202625d ago Press Release Bullish 7/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
  10. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $4.18 Now $4.04 −3.35% settles Jan 5
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 12m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026